摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-甲基-3-吡啶硫醇 | 762272-47-9

中文名称
2-甲基-3-吡啶硫醇
中文别名
1-羧基乙基硬脂酸盐
英文名称
3-mercapto-2-methyl-pyridine
英文别名
2-S-methylmercaptopyridine;2-methylpyridine-3-thiol;meth ylmercaptopyridine
2-甲基-3-吡啶硫醇化学式
CAS
762272-47-9
化学式
C6H7NS
mdl
MFCD08436480
分子量
125.194
InChiKey
CGQWZVMVSJLPKO-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    8
  • 可旋转键数:
    0
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.166
  • 拓扑面积:
    13.9
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

  • 作为反应物:
    描述:
    1,3-环庚二酮2-甲基-3-吡啶硫醇原甲酸三乙酯硫酸 作用下, 反应 1.0h, 生成 2-(((2-methylpyridin-3-yl)thio)methylene)cycloheptane-1,3-dione
    参考文献:
    名称:
    Dione-thiophene conjugate inhibits proliferation and metastasis of nasopharyngeal carcinoma cells through calcium binding protein-P down-regulation
    摘要:
    In the present study a series of dione-thiophenol conjugates was prepared and evaluated against nasopharyngeal carcinoma (NPC) cells. MTT assay showed that compound 4a reduced proliferation of C666-1 and CNE-1 cells to 26 and 24%, respectively at 10 mu mol/l concentration. Flow cytometry revealed that increasing the concentration of compound 4a from 2 to 10 mu mol/l increased the proportion of early apoptotic C666-1 cells from 2.76 to 69.43%. A significant (P <0.001) decrease in the expression of S1OOP was caused by compound 4a. In compound 4a treated C666-1 cells the expression of RAGE, EGFR, CD44, MMP2 and MMP9 was markedly decreased. In summary, compound 4a inhibits nasopharyngeal cancer cell proliferation and induces apoptosis through down-regulation of S1OOP. Moreover, compound 4a also decreases MMP-2, MMP-9, EGFR, CD44 and RAGE expression in nasopharyngeal cancer cells. Thus, compound 4a can be investigated further as a drug candidate for the treatment of nasopharyngeal cancer. (C) 2019 Published by Elsevier Masson SAS.
    DOI:
    10.1016/j.ejmech.2019.01.051
点击查看最新优质反应信息

文献信息

  • PYRIMIDINE-FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
    申请人:SHANGHAI BLUERAY BIOPHARMA CO., LTD.
    公开号:US20210053989A1
    公开(公告)日:2021-02-25
    Disclosed in the present disclosure are a pyrimidine-fused cyclic compound or a pharmaceutically acceptable salt, hydrate, prodrug, stereoisomer, solvate or isotope labeled compound thereof. Also provided in the present disclosure are a preparation method for the compound, a composition comprising the compound and a use of the compound for the preparation of a medicament for the prevention and/or treatment of a disease or condition associated with abnormal SHP2 activity.
    本公开涉及一种嘧啶融合的环状化合物或其药用可接受的盐、水合物、前药、立体异构体、溶剂合物或同位素标记化合物。本公开还提供了该化合物的制备方法、包含该化合物的组合物以及该化合物用于制备与异常SHP2活性相关的疾病或病况的药物的用途。
  • [EN] COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2<br/>[FR] COMPOSÉS ET COMPOSITIONS POUR INHIBER L'ACTIVITÉ DE SHP2
    申请人:NOVARTIS AG
    公开号:WO2016203405A1
    公开(公告)日:2016-12-22
    The present invention relates to compounds of formula I. The compounds are inhibitors of the Src Homolgy-2 phosphatase (SHP2) and thus useful in the treatment of Noonan Syndrome, Leopard Syndrome and cancer.
    本发明涉及式I的化合物。这些化合物是Src同源-2磷酸酶(SHP2)的抑制剂,因此在努南综合征、豹纹综合征和癌症的治疗中有用。
  • [EN] ARYLSULFONAMIDE DERIVATIVES AS MGLUR4 NEGATIVE ALLOSTERIC MODULATORS<br/>[FR] DÉRIVÉS D'ARYLSULFONAMIDE EN TANT QUE MODULATEURS ALLOSTÉRIQUES NÉGATIFS DE MGLUR4
    申请人:HOFFMANN LA ROCHE
    公开号:WO2021028512A1
    公开(公告)日:2021-02-18
    The present invention provides new arylsulfonamide compounds having the general formula (I), wherein L, R1, R2, R3 and R4are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds as mGLUR4 negative allosteric modulators.
    本发明提供了具有一般式(I)的新芳基磺酰胺化合物,其中L、R1、R2、R3和R4如本文所述,包括这些化合物的组合物,制造这些化合物的方法以及将这些化合物用作mGLUR4负变构调节剂的方法。
  • Novel 2-pyridinecarboxamide derivatives
    申请人:Mitsuya Morihiro
    公开号:US20060258701A1
    公开(公告)日:2006-11-16
    The present invention relates to a compound which has a glucokinase-activating effect and is useful as a therapeutic agent for diabetes mellitus, being represented by a formula (I): [wherein X 1 represents a nitrogen atom, sulfur atom, oxygen atom or the like; R 1 represents a 6- to 10-membered aryl group, 5- to 7-membered heteroaryl group or the like; D represents an oxygen atom or sulfur atom; R and R 3 are the same or different, each representing a hydrogen atom, lower alkyl group or the like; a formula (II) represents an optionally substituted 5- to 7-membered heteroaryl group or the like; a formula (III) represents a monocyclic or bicyclic heteroaryl group] or a pharmaceutically acceptable salt thereof.
    本发明涉及一种化合物,具有激活葡萄糖激酶的效果,并可用作糖尿病治疗剂,其化学式表示为(I):[其中X1表示氮原子、硫原子、氧原子或类似物;R1表示6-至10-成员芳基基团、5-至7-成员杂芳基基团或类似物;D表示氧原子或硫原子;R和R3相同或不同,分别表示氢原子、低碳基或类似物;式(II)表示可选取代的5-至7-成员杂芳基团或类似物;式(III)表示单环或双环杂芳基团]或其药学上可接受的盐。
  • Novel 2-Heteroaryl-Substituted Benzimidazole Derivative
    申请人:Nonoshita Katsumasa
    公开号:US20080070928A1
    公开(公告)日:2008-03-20
    A glucokinase activator is provided; and a remedy and/or a preventive for diabetes, or a remedy and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a remedy and/or a preventive for obesity are provided. A glucokinase activator characterized by containing a 2-heteroaryl-substituted benzimidazole derivative of a general formula (I-0) or its pharmaceutically-acceptable salt: [in the formula, X represents a carbon atom or a nitrogen atom; X 1 , X 2 , X 3 and X 4 each independently represent a carbon atom or a nitrogen atom; the ring A represents a 5- or 6-membered nitrogen-containing aromatic hetero ring of a formula (II): (in the formula, X represents a carbon atom or a nitrogen atom); R 1 represents an aryl, etc.; R 2 represents a hydroxy, etc.; R 3 represents a —C 1-6 alkyl, etc.; R 4 represents a —C 1-6 alkyl, etc.; X 5 represents —O—, etc.; a indicates an integer of 1, 2 or 3; q indicates an integer of from 0 to 2; m indicates an integer of from 0 to 2].
    提供了一种葡萄糖激酶激活剂;提供了糖尿病的治疗和/或预防,或者提供了糖尿病的治疗和/或预防,例如视网膜病变、肾病、神经病、缺血性心脏病、动脉硬化,以及肥胖症的治疗和/或预防。葡萄糖激酶激活剂的特征在于包含通式(I-0)的2-杂环芳基取代苯并咪唑衍生物或其药学上可接受的盐:[在公式中,X表示碳原子或氮原子;X1、X2、X3和X4分别独立地表示碳原子或氮原子;环A表示公式(II)的5-或6-成员含氮芳香杂环:(在公式中,X表示碳原子或氮原子);R1表示芳基等;R2表示羟基等;R3表示-C1-6烷基等;R4表示-C1-6烷基等;X5表示-O-等;a表示1、2或3的整数;q表示0到2的整数;m表示0到2的整数]。
查看更多

同类化合物

(S)-氨氯地平-d4 (R,S)-可替宁N-氧化物-甲基-d3 (R)-N'-亚硝基尼古丁 (5E)-5-[(2,5-二甲基-1-吡啶-3-基-吡咯-3-基)亚甲基]-2-亚磺酰基-1,3-噻唑烷-4-酮 (5-溴-3-吡啶基)[4-(1-吡咯烷基)-1-哌啶基]甲酮 (5-氨基-6-氰基-7-甲基[1,2]噻唑并[4,5-b]吡啶-3-甲酰胺) (2S)-2-[[[9-丙-2-基-6-[(4-吡啶-2-基苯基)甲基氨基]嘌呤-2-基]氨基]丁-1-醇 (2R,2''R)-(+)-[N,N''-双(2-吡啶基甲基)]-2,2''-联吡咯烷四盐酸盐 黄色素-37 麦斯明-D4 麦司明 麝香吡啶 鲁非罗尼 鲁卡他胺 高氯酸N-甲基甲基吡啶正离子 高氯酸,吡啶 高奎宁酸 马来酸溴苯那敏 马来酸左氨氯地平 顺式-双(异硫氰基)(2,2'-联吡啶基-4,4'-二羧基)(4,4'-二-壬基-2'-联吡啶基)钌(II) 顺式-二氯二(4-氯吡啶)铂 顺式-二(2,2'-联吡啶)二氯铬氯化物 顺式-1-(4-甲氧基苄基)-3-羟基-5-(3-吡啶)-2-吡咯烷酮 顺-双(2,2-二吡啶)二氯化钌(II) 水合物 顺-双(2,2'-二吡啶基)二氯化钌(II)二水合物 顺-二氯二(吡啶)铂(II) 顺-二(2,2'-联吡啶)二氯化钌(II)二水合物 非那吡啶 非洛地平杂质C 非洛地平 非戈替尼 非尼拉朵 非尼拉敏 阿雷地平 阿瑞洛莫 阿培利司N-6 阿伐曲波帕杂质40 间硝苯地平 间-硝苯地平 锇二(2,2'-联吡啶)氯化物 链黑霉素 链黑菌素 银杏酮盐酸盐 铬二烟酸盐 铝三烟酸盐 铜-缩氨基硫脲络合物 铜(2+)乙酸酯吡啶(1:2:1) 铁5-甲氧基-6-甲基-1-氧代-2-吡啶酮 钾4-氨基-3,6-二氯-2-吡啶羧酸酯 钯,二氯双(3-氯吡啶-κN)-,(SP-4-1)-